Articles tagged with: Celgene
Headline, News »
A group of mainly European multiple myeloma researchers has issued a statement regarding the potential link between Revlimid and secondary cancer.
According to the statement, the group initially met in Paris on February 23, 2011 at a meeting arranged by Celgene, the company that developed and markets Revlimid (lenalidomide).
The group includes 12 well-known multiple myeloma researchers, almost entirely from Europe. Among the group’s members are investigators from the CALGB 100104, IFM 2005-02, and MM-015 clinical trials, which are the three trials that last December reported data suggesting a possible…
Headline, News »
Several investment bank reports published this week have heightened concern about a potential link between Revlimid and second cancers in multiple myeloma patients. The reports have unnerved investors to such a degree that the stock of Celgene, Revlimid’s manufacturer, is down almost nine percent since the middle of last week.
Apprehension about Revlimid (lenalidomide) and secondary cancer first surfaced in December during the American Society of Hematology (ASH) annual meeting. At the meeting, results were presented from three trials studying long-term Revlimid use. All three trials showed more…
Headline, News »
New information was released last week regarding long-term treatment with Revlimid and a multiple myeloma patient’s risk of developing a second cancer.
The information is based on analyses prompted by results from three clinical trials presented at the American Society of Hematology meeting last month. In each of the three trials, more multiple myeloma patients receiving Revlimid maintenance therapy reported developing a secondary cancer than patients who did not receive maintenance therapy.
Celgene, the manufacturer of Revlimid (lenalidomide), announced the results of the follow-up analyses during a quarterly…
Turkce »
Geçen ay, uzun süreli Revlimid tedavisi sonrası multipl miyelom hastalarında ikincil kanserlerin ortaya çıkmasıyla ilgili yeni bilgiler yayınlandı.
Bu bilgi, geçen Aralık’taki Amerikan Hematoloji Derneği toplantısında sunulan üç klinik deneyin sonuçlarının analizi sonucu ortaya çıkmıştır. Üç çalışmada da Revlimid idame tedavisi olan multipl miyelom hastalarında, idame tedavisi yapılmayan hastalarla karşılaştırıldığında daha çok ikincil kanserler gözlemlenmiştir.
Revlimid’in (Lenalidomid) üreticisi Celgene perşembe günü yatırımcılar ile olan çeyrek sonu telefon konferansında bu çalışmaların sonuçlarının analizini açıkladı.
Celgene’in CEO’su Robert Hugin ¨Revlimid idame tedavisi olan grupta daha yüksek oranlarda ikincil kanserler gözlemlenmiş olsa da,…
News »
Celgene Seeks Expanded Approval For Revlimid In Europe – The pharmaceutical company Celgene announced on Tuesday that it is seeking expanded approval for Revlimid (lenalidomide) as treatment for multiple myeloma in Europe. The European Medicines Agency (EMA) will review approval of Revlimid for maintenance therapy of newly diagnosed myeloma patients who have not progressed after initial therapy with melphalan (Alkeran), prednisone, and Revlimid or after autologous stem cell transplantation. Currently, Revlimid is approved in combination with dexamethasone for the treatment of patients who have received at least one prior therapy. For more information, please see the Celgene press release.
ENMD-2076 Is Safe In Relapsed/Refractory Multiple Myeloma (ASH 2010) – The investigational drug ENMD-2076, which is being developed by the pharmaceutical company EntreMed, is safe in relapsed/refractory multiple myeloma patients, according to the interim Phase 1 trial results presented at the 2010 Meeting of the American Society of Hematology (ASH). Researchers tested four different dose levels (150 mg to 400 mg) in 28-day cycles. They observed progression of disease for all patients receiving the minimum dose of 150 mg. Patients receiving a dose of 300 mg achieved stable disease with reductions in serum M-protein. Researchers did not observe any dose-limiting side effects. Most side effects were mild to moderate and included nausea, diarrhea, and fatigue. The optimal dosage has not yet been determined as the trial is still ongoing. For more information, please see abstract 1957 on the ASH Meeting website and the clinical trial description.
Daratumumab Emerges As Potential Treatment In CD38-Positive Multiple Myeloma – Preclinical results showed that the experimental drug daratumumab is highly effective at killing cancerous cells that produce the CD38 molecule. The Danish biotechnology company Genmab is currently developing daratumumab for treatment of CD38-positive multiple myeloma tumors. Researchers initially tested a broad array of CD38 antibodies against more than 10 primary tumors from myeloma patients, and daratumumab was found to be the most effective at executing the immune system killing mechanisms. Genmab is currently conducting a Phase 1/2 study to determine the safety and optimal dosage of daratumumab. For more information, please see the study in the Journal of Immunology (abstract) and the clinical trial description.
PBOX-15 Induces Cell Death In Multiple Myeloma Cells – Preclinical results demonstrated that the experimental drug compound PBOX-15 (1,5-benzoxazepine-15), discovered by Irish clinical scientists, is a promising treatment for multiple myeloma. Researchers found that PBOX-15 induced cell death in four different lines of multiple myeloma cells. In two of the cell lines, PBOX-15 increased the number of death receptor genes to stimulate cell death. For more information, please see the study in the British Journal of Cancer (abstract).
